Molecular markers for radiation response in breast cancer
Part of Cancer, Injuries & trauma, Skin clinical trials.
This trial looks for biomarkers (biological signs) in breast tissue that might predict how well breast cancer responds to radiation therapy. It is for patients with ductal carcinoma in situ (DCIS) who are scheduled to receive radiation after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with DCIS (ductal carcinoma in situ), an early form of breast cancer.
- Your doctor has recommended radiation therapy after surgery.
- You are not currently receiving or planning to receive chemotherapy or other systemic cancer treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for biomarkers (genetic clues) to predict how patients will react to radiation after breast-conserving surgery. It aims to create a model that can personalize treatment to reduce side effects.
This study uses a special test (DCISionRT) on tissue from your breast surgery to help doctors decide if radiation therapy is right for you after lumpectomy for DCIS (a non-invasive form of breast cancer). The goal is to personalize treatment based on your individual cancer characteristics.
This study looks at breast cancer samples taken by biopsy to see how tissue “molecular markers” relate to how you respond to therapy and how the cancer behaves. It may help researchers better match future treatments to the biology of your tumor.
This study looks at how breast reconstruction (rebuilding the breast shape) affects women who have had a mastectomy and need radiation therapy. It aims to see if reconstruction can be done safely and with good results when followed by radiation.
This study looks at proteins and imaging patterns (from tissue, fluid near the tumor, and blood) to better understand breast cancer markers. It may help researchers find clues that doctors can use to evaluate breast nodules and newly diagnosed invasive breast cancer.
This trial is studying tiny molecules in your blood (called microRNAs) to see if they can predict how well breast cancer responds to chemotherapy given before surgery. If you are starting neoadjuvant chemotherapy, this study may help personalize your treatment.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.